Preoperative serum CA125 level and age at diagnosis: An effective prognosis prediction tool for patients with early-stage endometrial cancer.

Abstract

OBJECTIVE:

To investigate the combined predictive value of the preoperative serum cancer antigen 125 (CA125) level and age at diagnosis among patients with early-stage endometrial cancer (EC) after initial treatment.

METHODS:

We retrospectively analyzed data from patients with early-stage EC from 1999 to 2015 in multiple institutions in China. All 447 patients received postoperative adjuvant radiotherapy for FIGO 2009 stage I and II EC with complete data on preoperative serum CA125 levels. All patients were divided into four groups according to the ESMO-ESGO-ESTRO risk classification. The predictive probability of 5-year overall survival (OS) and the sensitivity and specificity of CA125 and age were calculated.

RESULTS:

The median follow-up time was 59 months (3-201 months). The 5-year OS and disease-free survival rates were 94.4% and 89.1%. Multivariate analysis showed that the preoperative CA125 level and age at diagnosis were independent prognostic factors for 5-year OS. The area under the curve for CA125 combined with age at diagnosis for 5-year OS was .692, and the corresponding sensitivity and specificity were 68.2% and 68.2% (p < .002), which were significantly better than the corresponding values for CA125 or age alone. After all 447 patients were divided into four groups according to CA125 combined with age, the 5-year OS of the elderly and higher CA125 group was only 73.7%.

CONCLUSIONS:

Although preoperative CA125 had limited sensitivity in predicting the prognosis for early-stage EC after initial treatment, it remains a useful serum marker for risk assessment of early-stage EC. Combining CA125 with age may increase its predictive sensitivity.

• Authors: Shuai Sun, Lichun Wei, Lijuan Zou, Tiejun Wang, Zi Liu, Jianli He, Xiaoge Sun, Wei Zhong, Fengju Zhao, Xiaomei Li, Sha Li, Hong Zhu, Zhanshu Ma, Wenhui Wang, Fuquan Zhang, Xiaorong Hou, Ke Hu
• Journal: Asia-Pacific journal of clinical oncology (Asia Pac J Clin Oncol) Vol. 19 Issue 5 Pg. e258-e266 (Oct 2023) ISSN: 1743-7563 [Electronic] Australia
• PMID: 36352545 (Publication Type: Journal Article)
• Copyright: © 2022 The Authors. Asia-Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd.

Chemical References

• Biomarkers

Topics

• Female
• Humans
• Aged
• Neoplasm Staging
• Retrospective Studies
• Endometrial Neoplasms (surgery)
• Prognosis
• Biomarkers